ko	pathway	ratio_in_study	ratio_in_pop	p_value
ko05219	Bladder cancer	1/2	48/7206	0.0132787793657
ko05213	Endometrial cancer	1/2	62/7206	0.0171350384049
ko05221	Acute myeloid leukemia	1/2	63/7206	0.017410196569
ko05223	Non-small cell lung cancer	1/2	66/7206	0.0182354399325
ko04730	Long-term depression	1/2	78/7206	0.0215329464633
ko05214	Glioma	1/2	79/7206	0.0218074882852
ko05212	Pancreatic cancer	1/2	83/7206	0.0229052703599
ko03018	RNA degradation	1/2	84/7206	0.0231796195745
ko05220	Chronic myeloid leukemia	1/2	85/7206	0.0234539302686
ko05218	Melanoma	1/2	85/7206	0.0234539302686
ko05210	Colorectal cancer	1/2	86/7206	0.0237282024407
ko05211	Renal cell carcinoma	1/2	96/7206	0.026468805489
ko04650	Natural killer cell mediated cytotoxicity	1/2	97/7206	0.0267426539265
ko04720	Long-term potentiation	1/2	99/7206	0.0272902352371
ko04914	Progesterone-mediated oocyte maturation	1/2	104/7206	0.0286585143891
ko01521	EGFR tyrosine kinase inhibitor resistance	1/2	106/7206	0.0292055564002
ko04012	ErbB signaling pathway	1/2	109/7206	0.0300258305066
ko05215	Prostate cancer	1/2	111/7206	0.0305724873041
ko01522	Endocrine resistance	1/2	124/7206	0.0341220006542
ko04726	Serotonergic synapse	1/2	137/7206	0.0376650038921
ko05160	Hepatitis C	1/2	153/7206	0.0420166863035
ko04270	Vascular smooth muscle contraction	1/2	154/7206	0.0422883390224
ko04068	FoxO signaling pathway	1/2	167/7206	0.0458163189254
ko04910	Insulin signaling pathway	1/2	172/7206	0.0471715008106
ko05224	Breast cancer	1/2	174/7206	0.0477133039156